Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

NCT07363577 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

456

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: LB-102 (50 mg tablet)
DRUG: LB-102 (100 mg tablet)
OTHER: Placebo

Sponsor

LB Pharmaceuticals Inc.